In draft guidance, published today (9 February 2010), the National Institute for Health and Clinical Excellence (NICE) has been unable to recommend everolimus (afinitor, Novartis) for the second line treatment of advanced renal cell carcinoma. This draft guidance is now available for public consultation. Consultees, healthcare professionals and members of the public are able to comment on the recommendations which are available from 9 February until 2 March 2010 on the NICE website. Comments received during this consultation will be fully considered by the Appraisal Committee in March. Following this, the next draft guidance will be issued.
The drug pazopanib (Votrient) slowed the progression of advanced renal cell carcinoma (RCC), a form of kidney cancer, in patients by 54% percent, according to a new study published in the Journal of Clinical Oncology. "Advanced renal cell carcinoma remains a challenging disease, but the outlook for patients has improved in the past year - including the addition of pazopanib, which targets multiple pathways within cancer cells, " study author Dr. Cora N. Sternberg, chief of the medical oncology department at the San Camillo and Forlanini Hospital in Rome, Italy, said in a news release from the American Society of Clinical Oncology. Dr.
Launch Of Ipsen's Decapeptyl R 6-Month Formulation LP 22.5 Mg In France For The Treatment Of Prostate Cancer
Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announce the launch by Ipsen in France of Decapeptyl(R) LP 22.5 mg 6-month sustained-release formulation for the treatment of locally advanced or metastatic hormone-dependent prostate cancer. Other launches are planned shortly, notably in Germany and Portugal. The marketing authorisation (MA) to this 6-month sustained-release formulation of Decapeptyl(R) (triptorelin embonate 22.
New research from the University of Alabama at Birmingham (UAB) says low potassium levels produce an increased risk of death or hospitalization in patients with heart failure and chronic kidney disease (CKD). In findings reported in January in Circulation: Heart Failure, a journal of the American Heart Association, the researchers say that even a mild decrease in serum potassium level increased the risk of death in this patient group. "Hypokalemia, or low potassium, is common in heart-failure patients and is associated with poor outcomes, as is chronic kidney disease, " said C. Barrett Bowling, M.D., a fellow in the UAB Division of Gerontology, Geriatrics and Palliative Care.
Carlos Slim Institute Of Health To Fund Genomic Research On Cancer, Type 2 Diabetes, And A Form Of Kidney Disease
Mexican business leader Carlos Slim HelĂ today announced the launch of a major research project in genomic medicine that will help accelerate progress in public health in Mexico and around the world. The project will be carried out by the Carlos Slim Institute of Health in partnership with the Broad Institute of MIT and Harvard and the National Institute for Genomic Medicine of the Mexican Secretariat of Health. The major goal is to understand the genomic basis of cancer in worldwide populations and of type 2 diabetes in Mexican and Latin American populations. The project, called Slim Initiative for Genomic Medicine, will last three years and will receive US $65M in support from the Carlos Slim Institute of Health.
Use Of A Modified Syringe Barrel To Ensure Control Of The Amplatz Sheath During Percutaneous Nephrolithotripsy In Obese Patients
UroToday.com - The morbidly obese patient is not an uncommon presentation for renal stone disease requiring percutaneous nephrolithotomy. These patients can often be a challenge even with the extra long Amplatz sheath to access the intra renal collecting system. One trick that we have used at our center is to place heavy 0-silk sutures onto the distal edge of the percutaneous access sheath and secure these with a mosquito clamp at the flank in order to retrieve the sheath, even if it is below the skin level. However, this still makes advancing the scope, through the subcutaneous fat, into the top of the sheath challenging during the repeated removal and insertion of the scope required for lithotripsy and stone extraction.